Evinacumab for Homozygous Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo. The primary outcome was the percent change from baseline in the LDL cholesterol level at week 24. RESULTS: The mean baseline LDL cholesterol level in the two groups was 255.1 mg per deciliter, despite the receipt of maximum doses of background lipid-lowering therapy. At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group, for a between-group least-squares mean difference of -49.0 percentage points (95% confidence interval [CI], -65.0 to -33.1; P<0.001); the between-group least-squares mean absolute difference in the LDL cholesterol level was -132.1 mg per deciliter (95% CI, -175.3 to -88.9; P<0.001). The LDL cholesterol level was lower in the evinacumab group than in the placebo group in patients with null-null variants (-43.4% vs. +16.2%) and in those with non-null variants (-49.1% vs. -3.8%). Adverse events were similar in the two groups. CONCLUSIONS: In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In total, 65 patients with HoFH were randomized to evinacumab (15 mg per kilogram body weight intravenous) or placebo every 4 weeks. Evinacumab lowered LDL-C by − 49% compared with placebo without a significant increase in adverse events. Evinacumab also significantly reduced ApoB-100 by − 37%, non-HDL by − 52%, total cholesterol by − 48%, triglycerides by − 50%, and ApoC-III by − 90%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison, evinacumab, a monoclonal antibody against ANGPTL3 that is thought to cause near-total suppression of ANGPTL3 activity, 7,14,15 reduces ApoB levels by >40% in adults with refractory hypercholesterolemia or homozygous familial hypercholesterolemia in its intravenous formulation administered at a dose of 15 mg/kg.14,15”
From Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ELIPSE HoFH trial, evinacumab significantly reduced LDL-C levels by 49% from baseline in patients with homozygous familial hypercholesterolemia (HoFH)—a population in whom standard lipid-lowering therapies (including statins and PCSK9 inhibitors) are often ineffective due to absent or defective LDL receptors [53].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings are confirmed in the recently published ELIPSE trial (Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia), which showed a similar LDL-C lowering effect of Evinacumab in patients with hoFH with null/null and non-null/null variants.20”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationCuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationMolecular genetics of the LDL receptor gene in familial hypercholesterolemia
Hobbs, H. H., Brown, M. S., & Goldstein, J. L. (1992) · Human Mutation · doi:10.1002/humu.1380010602 · Cited by 921
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationRaal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
Self-citationKöster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427
ANGPTL3 inhibition in homozygous familial hypercholesterolemia
Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705994 · Cited by 323
Self-citationShimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252827.51626.89 · Cited by 297
Cited by
Items 401–500 of 809
Recent insights into low-density lipoprotein metabolism and therapy
Pirillo, A., Catapano, A. L., & Norata, G. D. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000727 · Cited by 7
Use of apheresis in the age of new therapies for familial hypercholesterolaemia
Thompson, G. R. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000784 · Cited by 7
Xu, Y., Guo, J., Zhang, L., Miao, G., Lai, P., Zhang, W., Liu, L., Hou, X., Wang, Y., Huang, W. Y., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.840358 · Cited by 9
“For example, evinacumab, an antibody that inhibits ANGPTL3 not only reduces TG level in circulation by enhancing LPL activity but also significantly decreases low-density lipoprotein cholesterol (LDL-C) in patients with familial hypercholesterolemia (FH) in two independent phase 3 trials (5, 6).”
BackgroundDu, Z., Du, Y., Li, L., Sun, H., Hu, C., Jiang, L., Wang, L., & Qin, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020483 · Cited by 9
“If left undiagnosed and untreated, HoFH patients can develop markedly premature atherosclerotic cardiovascular disease (ASCVD) and die at an early age [10,11].”
BackgroundInhibiting angiopoietin-like protein 3: clear skies or clouds on the horizon?
Hegele, R. A. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae068 · Cited by 7
Ezetimibe in the management of homozygous familial hypercholesterolaemia
Mansfield, B. S., Dello-Iacono, A., & Raal, F. J. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.11.003 · Cited by 7
Self-citationMaidman, S. D., & Rosenson, R. S. (2025) · BioDrugs · doi:10.1007/s40259-025-00731-3 · Cited by 8
“ANGPTL3 was first pharmacologically targeted by a human mAb, evinacumab, which reduced LDL cholesterol levels by 49% among patients with homozygous FH, prompting it be FDA-approved for LDL cholesterol lowering only in this patient population [81].”
Self-citationQiu, Z., Wang, R.-Y., Zhang, Y., Huang, H.-B., He, R.-Y., Yan, H., Luo, P., Yang, B., Xu, Z.-F., & He, Q.-J. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01729-x · Cited by 9
Self-citationPradhan, A. K., Thandi, P., Mahajan, K., Iellamo, F., Perrone-Filardi, P., & Perrone, M. A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.059 · Cited by 6
The Role of Physical Activity and Exercise in Preventive Cardiology
Thompson, P. D. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.002 · Cited by 8
Gu, J., Sanchez, R. J., Chauhan, A., Fazio, S., & Rosenson, R. S. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.10.001 · Cited by 6
Self-citationWhite, R. T., Sankey, K. H., & Nawarskas, J. J. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000522 · Cited by 6
“18 These reductions in LDL were similar to that of high-intensity statin therapy.”
Saghafi, S., Chamani, E., Salmani, F., Fadaei, R., Shafiei, E., Moradi, N., & Tavakoli, T. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01905-0 · Cited by 6
“While certain studies have identified a negative correlation between ANGPTL8 and TG in patients with T2DM, conflicting findings have also been reported [23, 24].”
Advances in familial hypercholesterolemia
Paquette, M., & Baass, A. W. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.02.004 · Cited by 6
Review of Recent Literature and Updates in Nonstatin Cholesterol Management
Wang, E. M., Asias-Dinh, B. D., & Rosario, N. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.03.001 · Cited by 7
Lomitapide: navigating cardiovascular challenges with innovative therapies
Munkhsaikhan, U., Ait‐Aissa, K., Sahyoun, A. M., Apu, E. H., Abidi, A. H., Kassan, A., & Kassan, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10003-y · Cited by 6
“Patients with HoFH do not survive beyond the age of 30 [ 16, 17].”
An up-to-date review of emerging biologic therapies for hypercholesterolemia
Tomlinson, B. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2442455 · Cited by 6
“…ELIPSE HoFH (Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia) trial in patients with homozygous FH, evinacumab 15 mg/kg IV every 4 weeks (Q4W) reduced LDL cholesterol by a mean of 49% compared with placebo after 24 weeks regardless of LDLR function [58].”
Gu, J., Ma, X., Park, J.-N., Li, Y., & Sanchez, R. J. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.11.004 · Cited by 7
Bihorel, S., Dingman, R. K., Mendell, J., Norman, K. C., George, R. T., Zhao, X.-Q., Pordy, R. C., Garcia, D., Putnam, W. S., Raghuveer, G., et al. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70017 · Cited by 8
Self-citationSotin, T., Ge, X., Schönke, M., Vince, L., Thouzeau, A., Frey, S., Lorant, V., Krul, L., Pronk, A. C. M., Lalai, R. A., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf097 · Cited by 6
Innovative Lipid-Lowering Strategies: RNA-Based, Small Molecule, and Protein-Based Therapies
Jang, A. Y., Rhee, E., & Choi, S. H. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2691 · Cited by 7
“In HoFH patients ( n = 153), evinacumab increased the clearance rate of IDL by 616%, LDL by 131%, and VLDL by 16%, showing efficacy even in patients with minimal LDL-R activity [59].”
New therapeutic approaches for the treatment of hypertriglyceridemia
Gouni‐Berthold, I., & Schwarz, J. (2022) · Herz · doi:10.1007/s00059-022-05113-x · Cited by 6
Generation of a familial hypercholesterolemia model in non-human primate
Sato, A., Tsukiyama, T., Komeno, M., Iwatani, C., Tsuchiya, H., Kawamoto, I., Murase, M., Nakagawa, T., Itagaki, I., Seita, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-42763-1 · Cited by 7
The era of targeted therapy for hyperlipidemia
Чубыкина, У. В., Tyurina, A. V., & Владиславович, Е. М. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6038 · Cited by 6
Chan, D. C., Ying, Q., & Watts, G. F. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000795 · Cited by 6
“Recent clinical trials have demonstrated that evinacumab can lower plasma LDL-cholesterol levels by up to 50% in FH [53,55].”
BackgroundHovland, A., Mundal, L. J., Veierød, M. B., Holven, K. B., Bogsrud, M. P., Tell, G. S., Leren, T. P., & Retterstøl, K. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1072108 · Cited by 10
“Also newer treatment options have been introduced including evinacumab, a monoclonal antibody inhibiting the angiopoetin-like 3, a hormone regulating the lipoprotein lipase (Raal et al., 2020).”
BackgroundWill evinacumab become the standard treatment for homozygous familial hypercholesterolemia?
Doggrell, S. A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1862083 · Cited by 6
Surma, S., Romańczyk, M., & Filipiak, K. J. (2021) · Folia Cardiologica · doi:10.5603/fc.2021.0005 · Cited by 6
Identifying the Lipidomic Effects of a Rare Loss-of-Function Deletion in ANGPTL3
Blackburn, N. B., Meikle, P. J., Peralta, J. M., Kumar, S., Leandro, A. C., Bellinger, M. A., Giles, C., Huynh, K., Mahaney, M. C., Göring, H. H. H., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003232 · Cited by 6
Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia
Pirillo, A., & Catapano, A. L. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac028 · Cited by 6
Kronenberg, F., Borén, J., & Ray, K. K. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120487 · Cited by 6
Silbernagel, G., Higbie, H., Meininger, T., Lemen, D., Li, H., Chen, Y., Wen, Y., Zhen, Y., Qian, Y., Korovianskaia, P., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120485 · Cited by 6
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Dysregulated Lipid Metabolism as a Central Driver of Atherosclerotic Plaque Pathology
Steinbeck, J. E., Iannotti, R. A., & Rasheed, A. (2025) · Lipidology · doi:10.3390/lipidology2040017 · Cited by 6
“…antibody Evinacumab has been approved for patients with persistent hypercholesterolemia, such as those with homozygous FH, which decreases circulating LDL cholesterol levels [284,285]. cholesterol is taken up from the circulation by apolipoprotein-B100 (Apo-B100) binding to the LDL receptor (LDLR).”
Focused update 2025 delle linee guida ESC/EAS 2019 per il trattamento delle dislipidemie
Mach, F., Koskinas, K. C., van Lennep, J. E. R., Tokgözoğlu, L. S., Badimón, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., Backer, G. D., et al. (2025) · Giornale Ialiano di Cardiologia · doi:10.1714/4586.45945 · Cited by 11
Cicero, A. F. G., Mahjoubin-Tehran, M., Reiner, Ž., Eid, A. H., Jamialahmadi, T., & Sahebkar, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100110 · Cited by 5
ANGPTL3 and residual atherosclerotic risk: from lipid metabolism to therapeutic targeting
Weng, S., Ding, C., Lin, J., & Chai, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1706091 · Cited by 6
“Evinacumab signi fi cantly reduces LDL-C and non-HDL-C on top of maximally tolerated standard therapy and is approved for HoFH (10).”
InfluentialRay, K. K., & Kronenberg, F. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120636 · Cited by 6
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering
Gaudet, D., Larouche, M., Raal, F. J., & Catapano, A. L. (2026) · Circulation Research · doi:10.1161/circresaha.126.327270 · Cited by 5
Self-citationReview of Lipid-Lowering Therapy in Women from Reproductive to Postmenopausal Years
Witting, C. S., Devareddy, A., & Rodríguez, F. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2305183 · Cited by 7
“patients with refractory HLD, evinacumab reduces LDLC by >50% [56,57].”
BackgroundChong, E. W., Joncas, F., Douville, P., Bachvarov, D. R., Diorio, C., Calon, F., Bergeron, A.-C., Blais, J., Leung, S. O. A., Seidah, N. G., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02038-8 · Cited by 7
“Evinacumab is a monoclonal antibody (mab) that inhibits ANGPTL3 and is approved for treating homozygous hypercholesterolemia [18].”
BackgroundQureshi, Z. A., Khanzada, M., Safi, A., Fatima, E., Altaf, F., & Vittorio, T. J. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001945 · Cited by 6
“It bene fi ts patients with null LDLR variants of HoFH, differentiating it from PCSK9 inhibitors, which are of limited importance in such cases [79,80] .”
BackgroundRangwala, H. S., Fatima, H., Ali, M., Shafique, M. A., Rangwala, B. S., Virwani, V., Kumar, A., Arsal, S. A., Raja, A., Raja, S., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00649-1 · Cited by 7
“In the trial by Raal et al., adverse events occurred in 66% of patients in the evi-nacumab group and 81% in the placebo group during the treatment period [15].”
InfluentialTaha, H., Kandil, H., Badran, H. M., Farag, N. M., Khamis, H., Nasr, G. M., Samy, M., Abdrabou, M., Abuelezz, M., & Shaker, M. M. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00562-7 · Cited by 5
Wadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70005 · Cited by 6
Multilayer regulation of postprandial triglyceride metabolism in response to acute cold exposure
Zhang, Y., Zhou, S., Zhao, R., Xiong, C., Huang, Y., Zhang, M., & Wang, Y. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100751 · Cited by 6
“The first A3 inhibitory antibody has been approved for treating patients with homozygous familial hypercholesterolemia (43), with more inhibitors in clinical trials (44).”
Self-citationKholaif, N., Batha, L., Aljenedil, S., Awan, Z. A., Alruwaili, N., Habib, A. K., Jouda, A. A., Savo, M. T., Elmula, F. E. M. F., Mohamed, T. I., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119214 · Cited by 6
Lipid clinical trials with special reference to Indian population
Aseem Basha, M., & Ramakrishnan, S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.02.003 · Cited by 7
Schatoff, D., Jung, I. Y., & Goldberg, I. J. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.05.009 · Cited by 5
Treatment of Homozygous Familial Hypercholesterolemia
Cegla, J., Walji, S., Barton, L., Neuwirth, C. K. Y., & Thompson, G. R. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101708 · Cited by 9
Yarmolinsky, J. W., Lee, M. A., Lau, E., Moratalla-Navarro, F., Vincent, E. E., Li‐Gao, R., Rensen, P. C. N., van Dijk, K. W., Tsilidis, K. K., Sangphukieo, A., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf137 · Cited by 5
Regulatory Non-Coding RNAs in Familial Hypercholesterolemia, Theranostic Applications
Alikhani, H. K., Pourhamzeh, M., Seydi, H., Shokoohian, B., Hossein‐Khannazer, N., Jamshidi‐Adegani, F., Al‐Hashmi, S., Hassan, M., & Vosough, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.894800 · Cited by 6
Control of residual dyslipidaemic risk
Braunwald, E. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac359 · Cited by 5
Update Lipidologie: Evidenzbasierte Behandlung von Fettstoffwechselstörungen
Parhofer, K. G. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01536-8 · Cited by 10
Harada‐Shiba, M., Haruna, S., & Kogawa, N. (2024) · Future Cardiology · doi:10.2217/fca-2023-0136 · Cited by 6
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia
ALGhasab, N. S., Fogacci, F., Арманович, А. А., & Cicero, A. F. G. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406270 · Cited by 5
Xu, F., Shen, L., Yang, Y., Kong, L., Zu, W., Tian, D., Xuanchao, C., & Huang, G. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s411483 · Cited by 5
Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPLT3
Landmesser, U., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa790 · Cited by 6
Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02337-1 · Cited by 4
“…evinacumab significantly reduced LDL-C levels by 49% from baseline in patients with homozygous familial hypercholesterolemia (HoFH)—a population in whom standard lipid-lowering therapies (including statins and PCSK9 inhibitors) are often ineffective due to absent or defective LDL receptors [53 ].”
Emerging therapies for refractory hypercholesterolemia: a narrative review
Pawlos, A., Khoury, É., & Gaudet, D. (2024) · Future Cardiology · doi:10.1080/14796678.2024.2367860 · Cited by 5
Self-citationTan, L., Wang, N., Galema‐Boers, A. M. H., der Zee, L. V. V., van Lennep, J. E. R., Mulder, M. T., Lu, X., Danser, A. H. J., & Verdonk, K. (2024) · MedComm · doi:10.1002/mco2.681 · Cited by 5
Cheeley, M. K., Kirkpatrick, C. F., Brown, E. E., Dixon, D. L., Gunter, H., Osborn, D., & Wilkinson, M. J. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.002 · Cited by 15
Nasser, M., Mohammed, H. E., Haseeb, M. E., Darwish, M. K., Hanen, G., Abdelaziz, N. A., Heiba, A. H., Shata, A., & Abdelkader, M. S. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07764-4 · Cited by 4
“In phase 3 of, randomized, placebo-controlled trial (ELIPSE HoFH), its addition to the maximum doses of lipid-lowering therapy resulted in a 47.1% reduction in LDL cholesterol from base-line, compared to a 1.9% increase in the placebo group [10].”
InfluentialEmerging drug delivery strategies for local immunomodulation in atherosclerosis
Nunes, C., Kramer, A., & Volpatti, L. R. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114261 · Cited by 6
Erbasan, E., Aliciaslan, M., Erendor, F., Şanlioğlu, A. D., & Şanlıoğlu, S. (2025) · Gene Therapy · doi:10.1038/s41434-025-00575-0 · Cited by 8
Lipid lowering therapies in chronic kidney disease: A call to action
Ruiz, J. M., Arroyo, D., de Cos, M., Fernández, M. R., Sánchez-Álvarez, E., Bores, P. G., Hernández, J. L., & Corral, P. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120563 · Cited by 4
An Overview of Familial Hypercholesterolemia in Children and Adolescents–The Story So Far
Strati, M., Karatza, A., Sinopidis, X., & Kostopoulou, E. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.004 · Cited by 4
Evinacumab in patients aged 5–17 years with homozygous familial hypercholesterolemia
Rosenson, R. S., Brinton, E. A., Gaudet, D., Raal, F. J., Baker-Smith, C. M., Moriarty, P. M., Greber‐Platzer, S., Bergeron, J., McCrindle, B. W., Waldron, A., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120627 · Cited by 7
Self-citationPeng, D., Wang, L., Pi, L., XU, Y., Chen, J. L., Wu, P. Y., Wang, N., Chen, X., Qi, S., Feng, S. J., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2025.4878 · Cited by 4
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima, A., Serruys, P. W. J. C., Garg, S., McEvoy, J. W., Wood, D., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., et al. (2026) · EuroIntervention · doi:10.4244/eij-d-25-00598 · Cited by 5
Self-citationGenetic factors contributing to atherosclerosis
Raddatz, M. A., Allayee, H., & Lusis, A. J. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001286 · Cited by 4
Ginsberg, H. N., & Bornfeldt, K. (2026) · Circulation Research · doi:10.1161/circresaha.125.327267 · Cited by 4
AAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trial
Zheng, T., Gao, G., Xu, C. B., Li, R. F., Shao, J., Wang, X., Han, X., Li, J., Liu, P. N., Xiong, Y., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04441-3 · Cited by 4
“Angiopoietin-like 3 (ANGPTL3) inhibitors have demonstrated effective LDL-C lowering through non-LDLR-dependent clearance 7 .”
Hyperlipidemia: effective disease management with a focus on PCSK9 inhibitors
Shaw, P. B. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88606 · Cited by 4
Updates in the management of pediatric dyslipidemia
Choudhari, P., & Patni, N. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000879 · Cited by 4
“Loss of function and inhibition of ANGPTL3 have led to decreased triglycerides, LDLC, and risk of coronary artery disease [31].”
BackgroundMethodInfluentialUpdates on Non-Statin LDL-Lowering Therapy
Abdulla, A., Shalaby, M., Kumfa, P. N., Raja, M. W., Allencherril, J., & Sharifeh, T. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02028-3 · Cited by 5
“The ELIPSE HoFH trial was a double blind, placebo-controlled trial of 65 patients with HoFH already receiving maximum doses of LDL-lowering therapy that were randomized to receive an IV infusion of evinacumab at 15 mg/ kg of body weight once every 4 weeks versus placebo [27].”
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children
Reijman, M. D., Kusters, D. M., & Wiegman, A. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2330948 · Cited by 4
“Due to the mechanism of action, which is independent of the LDLR, evinacumab is also effective in patients with bi-allelic negative mutations in LDLR [26,27].”
BackgroundHubaud, A., & Singh, A. P. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.04.001 · Cited by 4
Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline
Xu, J., & Ashjian, E. J. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211053489 · Cited by 4
“Adverse events were similar between groups; nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, and nausea were more prevalent in the evinacumab group.(78) In February 2021, the FDA approved evinacumab (Evkeeza) as an adjunct to other LDL-C lowering therapies to treat HoFH in patients at least 12 years of…”
BackgroundInfluentialMedicinal chemistry and pharmacology of statins
Moore, B. M., II, & Cook, G. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00012-2 · Cited by 7
Weintraub, S. F., Schillow, J. A., Azari, B. M., & Hirsh, B. J. (2022) · JACC Case Reports · doi:10.1016/j.jaccas.2022.06.021 · Cited by 4
Update on management of paediatric dyslipidaemia
Bansal, N., Kumar, S., & Brar, P. C. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000794 · Cited by 4
Park, K., Vishnevetskaya, K., Vaidyanathan, J., Burckart, G. J., & Green, D. J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1973 · Cited by 4
An update on emerging drugs for the treatment of hypercholesterolemia
Nelson, A. J., Bubb, K. J., & Nicholls, S. J. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.2009801 · Cited by 5
Homozygous Familial Hypercholesterolemia
Young, L., Brown, E. E., & Martin, S. S. (2022) · JACC Case Reports · doi:10.1016/j.jaccas.2022.10.005 · Cited by 4
“Evinacumab has a unique mechanism of action that is independent of the LDL receptor; it reduces LDL-C levels through up-regulation of lipoprotein lipase and endothelial lipase.(5,6) Limitations include its cost and intravenous route of administration, potentially leading to access challenges.”
BackgroundGenetic risk and its role in primary prevention of CAD
Roberts, R., Chavira, J., & Venner, E. (2022) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2022.07 · Cited by 4
ANGPTL3 Variants Associate with Lower Levels of Irisin and C-Peptide in a Cohort of Arab Individuals
Alanbaei, M., Abu‐Farha, M., Hebbar, P., Melhem, M., Chandy, B., Anoop, E., Cherian, P., Al‐Khairi, I., Alkayal, F., Al‐Mulla, F., et al. (2021) · Genes · doi:10.3390/genes12050755 · Cited by 4
“However, the trial assessed only a small number of patients for a limited period where long term safety and cardiovascular outcomes risk have not been fully examined [18].”
BackgroundMethodFactoring in ANGPTL3 When LDL Is Refractory
Martin, S. S. (2020) · New England Journal of Medicine · doi:10.1056/nejme2032798 · Cited by 5
Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management
Ying, Q., Chan, D. C., & Watts, G. F. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000747 · Cited by 4
Evinacumab Therapy for Homozygous Familial Hypercholesterolemia
Toth, P. P. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100646 · Cited by 4
AlRuthia, Y. S., Almutairi, K. K., Aljammaz, N. A., Alsuwayegh, A., Alanazi, M. A., AlSulaiman, R. F., Alfaori, T. M., & Alabdan, N. (2025) · Healthcare · doi:10.3390/healthcare13192428 · Cited by 5
“…9 (PCSK9) Inhibitors (e.g., evolocumab, alirocumab), small interfering RNA (siRNA) treatment (e.g., inclisiran), and angiopoietin-like 3 (ANGPTL3) (e.g., Evinacumab) for patients who did not achieve their target LDL-C levels despite being on maximally tolerated statins and ezetimibe [10,13–15].”
ANGPTL3/8: one target, multiple lipid disorders
Zhang, R. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.10.003 · Cited by 3
Watts, G. F., Scott, R., Sullivan, D., BAKER, J., Clifton, P. M., Hamilton, J., Given, B. D., Melquist, S., Zhou, R., Gaudet, D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04307-8 · Cited by 3
Self-citationLiver transplantation in severe homozygous familial hypercholesterolaemia: a scoping review
Pang, J., Gidding, S. S., Kelty, E. A., Raal, F. J., Cuchel, M., Hudgins, L. C., Blom, D. J., Sorial, E., Russell, D. J., Ramachandra, D., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120730 · Cited by 3
Self-citationApplications of genome editing technologies in the treatment of human diseases
Alshorman, J., Mehran, M. J., Tembo, K. M., Mostafavi, N., Bolideei, M., & Wang, Y. L. (2026) · Gene Therapy · doi:10.1038/s41434-026-00627-z · Cited by 4
Li, Y., Zhou, X., Wen, Y., Huang, Q., Yang, X., Mukherjee, R., Sutton, R., Liu, T., Cai, W., & Huang, W. (2026) · Biomedicines · doi:10.3390/biomedicines14071574 · Cited by 3
“ANGPTL3, mainly produced by the liver, inhibits LPL and endothelial lipase and has the most advanced clinical development [150,153].”
The Role of Genetics in Advancing Cardiometabolic Drug Development
Abou-Karam, R., Cheng, F., Gady, S., & Fahed, A. C. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01195-6 · Cited by 4
Elenbaas, J. S., Lee, P. C., Patel, V., & Stitziel, N. O. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080905 · Cited by 3
Gomes, L. L. A., Faden, D. F., Xie, L., Chambers, S., Stone, C. J., Werth, V. P., & Williams, K. J. (2025) · Lupus Science & Medicine · doi:10.1136/lupus-2024-001160 · Cited by 3
Zhang, X., Liu, D., Qiu, Y., Hu, R., Chen, S., Xu, Y., Qian, C., Du, L., Yuan, J., & Li, X. (2025) · Metabolites · doi:10.3390/metabo15060352 · Cited by 4
“Research has demonstrated that pharmacological inhibition of ANGPTL3 by evervolumab and Vupanorsen mimics the phenotype associated with ANGPTL3 loss-of-function mutations [80,81].”
Metadata
- Authors
- Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., Khilla, N., Pordy, R., Weinreich, D. M., Yancopoulos, G. D., Zhang, Y., & Gaudet, D.
- Affiliations
- University of the Witwatersrand (ZA)
- Regeneron (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-08-20
- Volume
- 383
- Issue
- 8
- Pages
- 711-720
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3061843793
- Semantic Scholar
- 9f8bdc77b195a0ec05f5cb5d0662d5a8c5e0b865
- Cited by
- 793
- References
- 24
- Citations by year
- 2026: 126 · 2025: 129 · 2024: 139 · 2023: 123 · 2022: 130 · 2021: 123 · 2020: 22
- FWCI
- 91.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evinacumab, homozygous familial hypercholesterolemia, ANGPTL3, LDL cholesterol lowering, monoclonal antibodies, lipid-lowering therapy, atherosclerotic cardiovascular disease prevention
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adolescent, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Child, Double-Blind Method, Female, Homozygote, Humans, Hyperlipoproteinemia Type II, Infusions, Intravenous, Cholesterol, LDL, Male, Middle Aged, Mutation, Receptors, LDL, Least-Squares Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.